Navigation Links
Milestone for cannabinoid MS study
Date:7/21/2008

The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School in Plymouth has reached an important milestone with the news that the full cohort of 493 people with multiple sclerosis (MS) has been recruited to the study.

CUPID is a clinical trial which will evaluate whether tetrahydrocannabinol (THC), one of many compounds found in the in the cannabis plant (and the main active ingredient) is able to slow the progression of MS.

This is an important study for people with MS because current treatments either target the immune system in the early stages of MS, or are aimed at easing specific symptoms such as muscle spasms or bladder problems. At present there is no treatment which slows progression of the disease.

The CUPID trial follows an earlier study Cannabinoids and Multiple Sclerosis (CAMS) which suggested a link between THC and the slowing of MS. The CAMS trial saw participants take THC for a year the CUPID trial will last for longer and aims to assess the effect of THC on progressive MS.

It has taken two years to recruit the 493 participants who will each take part in the trial for three years, and in some cases three and a half years. After data cleaning and analysis the results should be available by spring/early summer 2012.

Professor John Zajicek from the Peninsula Medical School, who heads the team carrying out the CUPID study, said: "We are delighted to have achieved the correct number of patient participants for this trial. Patients have been recruited from 27 sites across the UK. If we are able to prove beyond reasonable doubt the link between THC and the slowing down of progressive MS, we will be able to develop an effective therapy for the many thousands of MS sufferers around the world."

The CUPID trial is funded by the Medical Research Council, the Multiple Sclerosis Society and the Multiple Sclerosis Trust.

Chris Jones, chief executive of the MS Trust, commented: "The MS Trust is delighted to be supporting this study on behalf of people with MS. The ability to halt progression in MS is what we dream of - the Holy Grail for those whose condition deteriorates year on year. This study should give us the definitive answer as to whether cannabinoids will prove to be such an agent."

Dr Laura Bell, research communications officer for the MS Society, said: "People affected by MS are keen to know whether there's any truth in the suggestion that elements of the cannabis plant can help ease the symptoms and slow down progression of the condition.

"The MS Society is supportive of safe clinical trials investigating the medicinal properties of cannabis and it's great news that this trial is going ahead. We look forward to the results of this exciting study."


'/>"/>

Contact: Andrew Gould
media@pr-works.co.uk
44-139-268-6107
The Peninsula College of Medicine and Dentistry
Source:Eurekalert

Related medicine news :

1. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
2. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
3. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
4. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
5. Smurfit-Stones Hodge, LA, Mill Becomes First to Achieve Safety Milestone
6. Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization
7. Milestone Scientific to Present at the Edgewater Research Investor Conference
8. Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007
9. Global Gene Map Clears New Milestone
10. Free Site Offering Patient-Physician Dialog Reaches Milestone
11. Marlo Thomas and St. Jude Childrens Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... billing and coding services, and Deyta Analytics, recently announced the recipients of the ... level of quality as measured from the caregiver’s point of view. The official ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions ... use of Microsoft Dynamics GP for one their long-term care clients. Working together ... Dynamics GP with key clinical management systems, and delivered a fully integrated accounting ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Society ... year, reproductive endocrinologists are required to report in vitro fertilization (IVF) ... dedicated to the practice of assisted reproductive technologies in the United States. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... BC and AD, saying it is time to set the record straight. Traditionally, BC ... this simply cannot possibly be true and offers explanation. , “To start with, the ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016  Marking its one year ... and ovarian cancer risk test, Color Genomics ... genes that highly impact the most common hereditary ... the Color Test analyzes hereditary cancer risks for ... uterine cancers. The Color Test is physician ordered ...
(Date:4/28/2016)... Dr. Vivek Ahuja , ... phen Schmidt Join the Growing ... solutions for life sciences, today announced key new leaders have joined ... to a growing business.  This will bolster the company,s safety business ... joined ArisGlobal in the position of Vice President - Safety. George ...
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
Breaking Medicine Technology: